Related Experiment Video

Updated: Jun 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Effects of felodipine on systemic and coronary haemodynamics in patients with angina pectoris

H Emanuelsson, A Hjalmarson, S Holmberg

    European Heart Journal
    |April 1, 1984
    PubMed

    Insights

    Felodipine, a dihydropyridine derivative, acts as a potent vasodilator, improving systemic and coronary blood flow in patients with coronary artery disease. Further research is needed to determine optimal dosing for ischemic heart disease treatment.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Coronary artery disease (CAD) poses significant challenges in cardiovascular treatment.
    • Dihydropyridine derivatives are explored for their vasodilatory properties.

    Purpose of the Study:

    • To investigate the systemic and coronary hemodynamic effects of felodipine in patients with CAD.
    • To assess felodipine's impact during rest and pacing-induced angina.

    Main Methods:

    • Cardiac catheterization was performed on 10 CAD patients.
    • Hemodynamic parameters were measured at rest and during pacing-induced angina.
    • Systemic arterial pressure, heart rate, cardiac index, and coronary sinus flow (CSF) were analyzed.

    Main Results:

    • Felodipine significantly decreased systemic arterial pressure and increased heart rate and cardiac index at rest.
    • Coronary sinus flow (CSF) increased by approximately 50%.
    • During pacing, felodipine maintained hemodynamic improvements without significantly altering myocardial lactate extraction or ST segment depression.

    Conclusions:

    • Felodipine is a potent systemic and coronary vasodilator.
    • It shows potential for treating hypertension, cardiac failure, and ischemic heart disease.
    • Further studies are required to establish optimal therapeutic doses for ischemic heart disease.

    More Related Videos

    Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine12:37

    Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

    Published on: February 9, 2016

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

    Published on: February 3, 2021

    Related Concept Videos

    Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

    Antihypertensive Drugs: Action of Calcium Channel Blockers

    Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...